ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA,” the "Company,” or "we”), an end-to-end commercial biopharmaceutical company ...

Net revenue for the first quarter of fiscal 2025 was $257.7 million. GAAP net loss for the first quarter of fiscal 2025 was $23.1 million, or a loss of $0.58 per basic share. Non-GAAP net income for ...

Third Quarter Total Revenue of $83.7 Million, an Increase of 7% Versus Prior Year. Total ARR of $347.8 Million, an Increase of 5% Versus Prior Year. Enterprise ARR of $256.9 Million, an Increase of 7% ...